BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...is involved in cartilage homeostasis, and high levels of the nucleoside may cause cartilage destruction. Lubris LLC...
...NASDAQ:FLXN), Burlington, Mass. Galapagos N.V. (Euronext Amsterdam:GLPG), NASDAQ:GLPG), Mechelen, Belgium GeneQuine Biotherapeutics GmbH, Hamburg, Germany Lubris LLC...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...two other assets: ECF843 and EV06 . Novartis gained exclusive, ex-European rights to ECF843 from Lubris LLC...
...N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kite Pharma Inc. (NASDAQ:KITE), Santa Monica, Calif. Lubris LLC...
BioCentury | Apr 14, 2017
Company News

Lubris, Novartis deal

...Novartis exercised an option for exclusive, ex-European rights to ECF843 recombinant human lubricin from Lubris for...
...completed a Phase II trial in dry eye. The partners declined to disclose financial terms. Lubris...
...Lubris BioPharma, Framingham, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Ophthalmic Alex Himes Recombinant human lubricin (rhLub) Lubris LLC Novartis...
BioCentury | Oct 24, 2016
Clinical News

Recombinant human lubricin: Clinical trial data

...hyaluronate. There were no treatment-related adverse events reported. Data were published in The Ocular Surface. Lubris...
...medical devices and that the product will be regulated as a biologic in the U.S. Lubris LLC...
BioCentury | Oct 26, 2009
Clinical News

Lubris preclinical data

...vs. untreated rats. Data were presented at the American College of Rheumatology meeting in Philadelphia. Lubris LLC...
Items per page:
1 - 5 of 5
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...is involved in cartilage homeostasis, and high levels of the nucleoside may cause cartilage destruction. Lubris LLC...
...NASDAQ:FLXN), Burlington, Mass. Galapagos N.V. (Euronext Amsterdam:GLPG), NASDAQ:GLPG), Mechelen, Belgium GeneQuine Biotherapeutics GmbH, Hamburg, Germany Lubris LLC...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...two other assets: ECF843 and EV06 . Novartis gained exclusive, ex-European rights to ECF843 from Lubris LLC...
...N.Y. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Kite Pharma Inc. (NASDAQ:KITE), Santa Monica, Calif. Lubris LLC...
BioCentury | Apr 14, 2017
Company News

Lubris, Novartis deal

...Novartis exercised an option for exclusive, ex-European rights to ECF843 recombinant human lubricin from Lubris for...
...completed a Phase II trial in dry eye. The partners declined to disclose financial terms. Lubris...
...Lubris BioPharma, Framingham, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Ophthalmic Alex Himes Recombinant human lubricin (rhLub) Lubris LLC Novartis...
BioCentury | Oct 24, 2016
Clinical News

Recombinant human lubricin: Clinical trial data

...hyaluronate. There were no treatment-related adverse events reported. Data were published in The Ocular Surface. Lubris...
...medical devices and that the product will be regulated as a biologic in the U.S. Lubris LLC...
BioCentury | Oct 26, 2009
Clinical News

Lubris preclinical data

...vs. untreated rats. Data were presented at the American College of Rheumatology meeting in Philadelphia. Lubris LLC...
Items per page:
1 - 5 of 5